Lipocine Inc
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation lon… Read more
Lipocine Inc (LPCN) - Total Assets
Latest total assets as of September 2025: $16.07 Million USD
Based on the latest financial reports, Lipocine Inc (LPCN) holds total assets worth $16.07 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Lipocine Inc - Total Assets Trend (2011–2024)
This chart illustrates how Lipocine Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Lipocine Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Lipocine Inc's total assets of $16.07 Million consist of 99.2% current assets and 0.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.6% |
| Accounts Receivable | $120.45K | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Lipocine Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lipocine Inc's current assets represent 99.2% of total assets in 2024, a decrease from 100.0% in 2011.
- Cash Position: Cash and equivalents constituted 27.6% of total assets in 2024, down from 70.7% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Lipocine Inc Competitors by Total Assets
Key competitors of Lipocine Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Lipocine Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Lipocine Inc generates 0.50x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Lipocine Inc generates $ 0.04 in net profit.
Lipocine Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.25 | 12.97 | 3.85 |
| Quick Ratio | 8.25 | 12.97 | 3.85 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $14.00 Million | $ 18.92 Million | $ 18.75 Million |
Lipocine Inc - Advanced Valuation Insights
This section examines the relationship between Lipocine Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.44 |
| Latest Market Cap to Assets Ratio | 1.67 |
| Asset Growth Rate (YoY) | -2.1% |
| Total Assets | $22.51 Million |
| Market Capitalization | $37.54 Million USD |
Valuation Analysis
Above Book Valuation: The market values Lipocine Inc's assets above their book value (1.67 x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Lipocine Inc's assets decreased by 2.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Lipocine Inc (2011–2024)
The table below shows the annual total assets of Lipocine Inc from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $22.51 Million | -2.13% |
| 2023-12-31 | $23.00 Million | -38.73% |
| 2022-12-31 | $37.54 Million | -28.47% |
| 2021-12-31 | $52.48 Million | +107.01% |
| 2020-12-31 | $25.35 Million | +28.97% |
| 2019-12-31 | $19.66 Million | -5.72% |
| 2018-12-31 | $20.85 Million | -17.66% |
| 2017-12-31 | $25.33 Million | -7.38% |
| 2016-12-31 | $27.34 Million | -39.74% |
| 2015-12-31 | $45.38 Million | +62.10% |
| 2014-12-31 | $27.99 Million | -39.29% |
| 2013-12-31 | $46.11 Million | +7990805.03% |
| 2012-12-31 | $577.00 | -98.22% |
| 2011-12-31 | $32.44K | -- |